2,500 patients to help unlock secrets of rare lymphoma
NCT ID NCT06449885
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 2,500 people newly diagnosed with marginal zone B-cell lymphoma to better understand the disease and how different treatments affect it. Researchers will track how long patients live without the cancer getting worse and how well various therapies work. The goal is to gather information to improve future care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a targeted drug boost standard therapy for a rare lymphoma?
- Smartwatches track hidden heart risk in blood cancer patients
- New drug combo aims to tackle Hard-to-Treat lymphoma